Major Finding: At 40 months' follow-up, 60% of the adalimumab patients who achieved remission remained in remission, compared with only 18.8% of those in the infliximab group.
Data Source: An open-label prospective cohort study.
Disclosures: Dr. Simonini reported no relevant financial disclosures.
ATLANTA — Adalimumab was more effective than infliximab for the prevention of recurrence of chronic childhood uveitis in a small open-label prospective study.
Remission was achieved within 10-12 weeks in 31 of the 33 children, including 15 of 16 recruited for the adalimumab group, and 16 of 17 recruited for the infliximab group. All were able to discontinue steroid treatment, and no significant differences were seen between the groups in time to remission or time to steroid discontinuation, Dr. Gabriele Simonini reported at the meeting.
At 40 months' follow-up, 60% of the adalimumab patients who achieved remission remained in remission, compared with only 18.8% of those in the infliximab group, said Dr. Simonini of the University of Florence (Italy).
Among those who relapsed, the median number of relapses was 1 (range, 1-3) in the adalimumab group, and 3 (range, 1-5) in the infliximab group.
The difference was statistically significant, Dr. Simonini said.